PANIXINE DISPERDOSE (cephalexin) by Signatur Biosciences is [see microbiology ( )] . Approved for respiratory tract infections caused by susceptible isolates of streptococcus pneumoniae, streptococcus pyogenes, otitis media caused by susceptible isolates of streptococcus pneumoniae and 11 more indications. First approved in 2003.
Drug data last refreshed 20h ago
[see Microbiology ( )] .
Worked on PANIXINE DISPERDOSE at Signatur Biosciences? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Oral Amoxicillin and Cephalexin PK/PD in Neonates
Cefadroxil and Cephalexin Drug Levels and Dosing in Pediatric Musculoskeletal Infections
A Study of Cephalexin Liquid in Healthy Participants
A Study of Cephalexin Suspension in Healthy Participants
A Study of Cephalexin Liquid for Pediatrics in Healthy Adults Participants